Medexus Pharmaceuticals Inc News - MDP

Suspension de la négociation par l'OCRCVM - MDP

Suspension de la négociation par l'OCRCVM - MDP Canada NewsWire VANCOUVER, BC, le 2 févr. 2021 VANCOUVER, BC, le 2 févr. 2021 /CNW/...

IIROC Trading Halt - MDP

IIROC Trading Halt - MDP Canada NewsWire VANCOUVER, BC, Feb. 2, 2021 VANCOUVER, BC, Feb. 2, 2021 /CNW/ - The following issues have been halted by...

Medexus Announces Renewal and Expansion of Canadian Distribution Agreement for NYDA®

TORONTO, CHICAGO and MONTREAL, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company”...

Medexus Submits Application to List on the Nasdaq

TORONTO, CHICAGO and MONTREAL, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company”...

Medexus Engages Independent Trading Group for Market Making Services

TORONTO and CHICAGO and MONTREAL, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the...

TMX Group, Medexus, C-Suite at The Open

TMX Group, Medexus, C-Suite at The Open Canada NewsWire TORONTO, Dec. 29, 2020 TORONTO, Dec. 29, 2020 /CNW/ - Ken d'Entremont, CEO, Medexus...

Medexus Announces Annual Equity Incentive Grants to Non-Executive Directors

TORONTO and CHICAGO and MONTREAL, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the...

Medexus (MDP.V) expands specialty pharmaceuticals portfolio

Medexus (MDP.V) expands specialty pharmaceuticals portfolio Canada NewsWire VANCOUVER, BC, Dec. 20, 2020 By Global Stocks News VANCOUVER, BC...

Medexus Enters into Exclusive License to Register and Commercialize Triamcinolone Hexacetonide (TH) in the United States with...

TORONTO and CHICAGO and MONTREAL, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the...

Medexus to Present at The 13th Annual LD Micro Main Event Conference on December 15th

TORONTO and CHICAGO and MONTREAL, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the...

Innovation Investor Conference Presentations Now Available for On-Demand Viewing

Innovation Investor Conference Presentations Now Available for On-Demand Viewing Canada NewsWire NEW YORK, Dec. 7, 2020 Individual and...

Live Innovation Investor Conference & Webinar: Public Company Presentations December 3rd

Live Innovation Investor Conference & Webinar: Public Company Presentations December 3rd Canada NewsWire NEW YORK, Nov. 30, 2020 Company...

Medexus Pharmaceuticals Reports Operating and Financial Results for the Three- and Six-Month Periods Ending September 30, 202...

TORONTO and CHICAGO and MONTREAL, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the...

Medexus Reaches 50% Enrollment in IXINITY® Phase 4 Clinical Trial Targeting Label Expansion for Pediatric Hemophilia B Pati...

TORONTO, CHICAGO and MONTREAL, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company”...

Medexus Pharmaceuticals Schedules Second Quarter Fiscal 2021 Conference Call

MONTREAL, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus) (TSXV:...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Medexus Pharmaceuticals Inc (MDP)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

MDP News

Suspension de la négociation par l'OCRCVM - MDP

IIROC Trading Halt - MDP

Medexus Announces Renewal and Expansion of Canadian Distribution Agreement for NYDA®

Medexus Submits Application to List on the Nasdaq

Medexus Engages Independent Trading Group for Market Making Services

TMX Group, Medexus, C-Suite at The Open

Medexus Announces Annual Equity Incentive Grants to Non-Executive Directors

Medexus (MDP.V) expands specialty pharmaceuticals portfolio

Medexus Enters into Exclusive License to Register and Commercialize Triamcinolone Hexacetonide (TH) in the United States with...

Medexus to Present at The 13th Annual LD Micro Main Event Conference on December 15th

Innovation Investor Conference Presentations Now Available for On-Demand Viewing

Live Innovation Investor Conference & Webinar: Public Company Presentations December 3rd

Medexus Pharmaceuticals Reports Operating and Financial Results for the Three- and Six-Month Periods Ending September 30, 202...

Medexus Reaches 50% Enrollment in IXINITY® Phase 4 Clinical Trial Targeting Label Expansion for Pediatric Hemophilia B Pati...

Medexus Pharmaceuticals Schedules Second Quarter Fiscal 2021 Conference Call

MDP Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Medexus Pharmaceuticals Inc (MDP) News

Medexus Pharmaceuticals Inc (MDP)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

MDP News

Suspension de la négociation par l'OCRCVM - MDP

IIROC Trading Halt - MDP

Medexus Announces Renewal and Expansion of Canadian Distribution Agreement for NYDA®

Medexus Submits Application to List on the Nasdaq

Medexus Engages Independent Trading Group for Market Making Services

TMX Group, Medexus, C-Suite at The Open

Medexus Announces Annual Equity Incentive Grants to Non-Executive Directors

Medexus (MDP.V) expands specialty pharmaceuticals portfolio

Medexus Enters into Exclusive License to Register and Commercialize Triamcinolone Hexacetonide (TH) in the United States with...

Medexus to Present at The 13th Annual LD Micro Main Event Conference on December 15th

Innovation Investor Conference Presentations Now Available for On-Demand Viewing

Live Innovation Investor Conference & Webinar: Public Company Presentations December 3rd

Medexus Pharmaceuticals Reports Operating and Financial Results for the Three- and Six-Month Periods Ending September 30, 202...

Medexus Reaches 50% Enrollment in IXINITY® Phase 4 Clinical Trial Targeting Label Expansion for Pediatric Hemophilia B Pati...

Medexus Pharmaceuticals Schedules Second Quarter Fiscal 2021 Conference Call

MDP Discussion

Your Recent History